Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–5 of 5 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: t(4;14) Clear all
Completed Phase 1 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
MFGR1877S
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
11
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced May 21, 2026, 7:25 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
PHA-739358
Drug
Lead sponsor
Nerviano Medical Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Scottsdale, Arizona • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced May 21, 2026, 7:25 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Mobile, Alabama • Alhambra, California • Santa Maria, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced May 21, 2026, 7:25 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
B-Cell Prolymphocytic Leukemia, Hypodiploidy, Loss of Chromosome 17p, Plasma Cell Leukemia, Progression of Multiple Myeloma or Plasma Cell Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Small Lymphocytic Lymphoma, t(14;16), t(4;14), T-Cell Prolymphocytic Leukemia, Waldenstrom Macroglobulinemia
Interventions
Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Seattle, Washington • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced May 21, 2026, 7:25 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Multiple Myeloma, Myeloma, Myeloma Multiple
Interventions
Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®), Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)
Drug
Lead sponsor
K36 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
San Francisco, California • Jacksonville, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced May 21, 2026, 7:25 PM EDT